Charles Schwab Investment Management Inc. Purchases 153,712 Shares of Celcuity Inc. (NASDAQ:CELC)

Charles Schwab Investment Management Inc. grew its position in Celcuity Inc. (NASDAQ:CELC) by 226.2% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 221,671 shares of the company’s stock after purchasing an additional 153,712 shares during the quarter. Charles Schwab Investment Management Inc. owned about 0.60% of Celcuity worth $3,305,000 as of its most recent SEC filing.

A number of other large investors also recently made changes to their positions in CELC. Wealth Enhancement Advisory Services LLC increased its position in Celcuity by 7.8% during the 2nd quarter. Wealth Enhancement Advisory Services LLC now owns 22,030 shares of the company’s stock worth $361,000 after buying an additional 1,600 shares during the period. Hennion & Walsh Asset Management Inc. bought a new position in Celcuity during the second quarter worth about $888,000. Bank of New York Mellon Corp raised its stake in Celcuity by 42.7% in the 2nd quarter. Bank of New York Mellon Corp now owns 66,256 shares of the company’s stock worth $1,085,000 after purchasing an additional 19,811 shares in the last quarter. Commonwealth Equity Services LLC boosted its holdings in Celcuity by 9.9% in the 2nd quarter. Commonwealth Equity Services LLC now owns 16,624 shares of the company’s stock valued at $272,000 after purchasing an additional 1,500 shares during the period. Finally, Rhumbline Advisers grew its position in shares of Celcuity by 27.7% during the 2nd quarter. Rhumbline Advisers now owns 32,464 shares of the company’s stock worth $532,000 after purchasing an additional 7,049 shares in the last quarter. Institutional investors own 63.33% of the company’s stock.

Celcuity Trading Down 0.7 %

Shares of CELC opened at $12.52 on Friday. The company has a debt-to-equity ratio of 0.65, a quick ratio of 10.36 and a current ratio of 10.35. Celcuity Inc. has a 52-week low of $11.51 and a 52-week high of $22.19. The firm has a market cap of $464.87 million, a price-to-earnings ratio of -4.80 and a beta of 0.74. The business’s fifty day moving average is $14.34 and its 200-day moving average is $15.48.

Wall Street Analyst Weigh In

A number of equities research analysts have recently weighed in on the stock. HC Wainwright reiterated a “buy” rating and issued a $27.00 price target on shares of Celcuity in a research report on Friday, November 15th. Lifesci Capital began coverage on Celcuity in a report on Monday, August 26th. They issued an “outperform” rating and a $27.00 price objective for the company. Stifel Nicolaus increased their target price on Celcuity from $39.00 to $42.00 and gave the stock a “buy” rating in a report on Monday, October 7th. Finally, Needham & Company LLC reaffirmed a “buy” rating and issued a $23.00 price target on shares of Celcuity in a research note on Friday, November 15th. Six equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, Celcuity presently has a consensus rating of “Buy” and a consensus price target of $29.17.

Celcuity Company Profile

Celcuity Inc, a clinical stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment.